ScholarIQanswers from OpenAlex

De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection

PaperCitations, authors & open-access status

De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection is a paper indexed in ScholarIQ from OpenAlex.

How many citations does De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection have?

ScholarIQcitation count

De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection has 66 citations in the OpenAlex counts ScholarIQ stores.

When was De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection published?

ScholarIQyear

De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection has 2010 year in the ScholarIQ index.

What is the open-access status of De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection?

ScholarIQoa status

De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection has closed oa status in the ScholarIQ index.

What is the DOI of De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection?

ScholarIQdoi

The DOI for De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection is on the source record.

What is the PMID of De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection?

ScholarIQpmid

The PMID for De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection is on the source record.

What is the OpenAlex record for De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection?

ScholarIQopenalex

The OpenAlex for De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial